Answers are grounded in this paper and cite their sources.
Increased antitumor immune response correlates with improved rates of pathologic complete response (pCR) in early HER2+ breast cancer (BC) patients treated with neoadjuvant anti-HER2 therapy. However, the systemic and local immune responses and temporal evolution in patients treated with neoadjuvant antibody-drug conjugates have not been investigated.
No takes yet. Share an insight, caveat, or question.
Zerdes et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: